PIK3CA related overgrowth spectrum

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
4 Unique sponsors
3 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase II: 6

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

6 trials
  • Merck Sharp & Dohme LLC Commercial
    MIRANSERTIB
    2022-500689-87-00 1 country 2021 n=19 Orphan
    Ended
  • Novartis Pharma AG Commercial
    ALPELISIB
    2023-508522-95-00 3 countries 2022 n=39 Orphan
    Ended
  • Novartis Pharma AG Commercial
    ALPELISIB
    2023-508530-34-00 6 countries 2021 n=164 Orphan
    Ended
  • Novartis Pharma AG Commercial
    ALPELISIB
    2024-519960-42-00 7 countries 2025 n=72 Orphan
    Recruiting
  • Relay Therapeutics Inc. Commercial
    RLY-2608
    2024-518895-30-00 7 countries 2025 n=99
    Recruiting
  • Centre Hospitalier Universitaire Dijon Bourgogne Academic
    IMP not specified
    2022-500197-34-01 1 country 2022 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 3 Phase II 1
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
Relay Therapeutics Inc. Commercial 1 Phase II 1
Centre Hospitalier Universitaire Dijon Bourgogne Academic 1 Phase II 1
New trials by year
2021
2
2022
2
2025
2
← All indication landscapes